On Mar. 6, 2020, Innovation Pharma announced that a second MTA has been signed to ship Brilacidin to a major U.S. university for analysis. One of worldﾒs leading coronavirus experts is overseeing the research. Innovation management is awaiting approval from the university to disclose additional details on the agreement and hopes to further inform shareholders next week regarding this development.